Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Tracon Pharmaceuticals, Inc. (TCON)
|
Add to portfolio |
|
|
|
| Price: |
$8.00
| | Metrics |
| OS: |
30.7
|
M
| |
|
|
| Market cap: |
$246
|
M
| |
|
|
|
Net cash:
|
$1.74
|
M
| |
$0.06
|
per share
|
|
EV:
|
$244
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($33.7)
|
M
| |
|
|
|
EBIT
|
($33.7)
|
M
| |
|
|
| EPS |
($1.20)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.3 | 0.0 | 0.0 | 3.0 | 8.8 | 3.4 | 7.9 |
| Revenue growth | -100.0% | | | -100.0% | -65.7% | 153.8% | -56.4% | 119.7% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.3 | 0.0 | 0.0 | 3.0 | 8.8 | 3.4 | 7.9 |
| Gross margin | | 100.0% | | | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 13.9 | 11.1 | 8.2 | 14.5 | 30.5 | 19.4 | 21.6 | 25.7 |
| General and administrative | 14.0 | 17.5 | 8.0 | 7.8 | 7.3 | 7.6 | 7.9 | 5.7 |
| EBIT | -27.9 | -28.3 | -16.2 | -22.3 | -34.7 | -18.2 | -26.0 | -23.5 |
| EBIT margin | | -8192.8% | | | -1158.0% | -208.0% | -753.1% | -296.9% |
| Pre-tax income | -29.1 | -28.7 | -16.8 | -22.7 | -35.0 | -19.1 | -27.0 | -24.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -29.1 | -28.7 | -16.8 | -22.7 | -35.0 | -19.1 | -27.0 | -24.4 |
| Net margin | | -8285.3% | | | -1165.3% | -218.2% | -783.1% | -309.2% |
| |
| Diluted EPS | ($1.39) | ($1.66) | ($1.87) | ($7.47) | ($12.97) | ($11.37) | ($2.13) | ($2.20) |
| Shares outstanding (diluted) | 20.9 | 17.3 | 9.0 | 3.0 | 2.7 | 1.7 | 12.7 | 11.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|